The purpose of the Supporting Fetal Alcohol Spectrum Disorders Screening and Intervention (FASD) program is to train primary care providers to reduce the incidence of prenatal alcohol exposure and improve developmental outcomes in children with suspected or diagnosed FASDs. To carry out special maternal and child health (MCH) projects of regional and national significance; to conduct training and research; to conduct genetic disease testing, counseling, and information development and dissemination programs; for the screening of newborns for sickle cell anemia, and other genetic disorders; to support comprehensive hemophilia diagnostic and treatment centers; and for increasing the capacity of pediatric providers to support families who have experienced sudden unexpected infant death or sudden unexplained death in childhood. These grants are funded with a set-aside from the MCH Block grant program. SPRANS grants are funded with 15 percent of the Block Grant appropriation of up to $600 million. When the appropriation exceeds $600 million, 12.75 percent of the amount over $600 million is set aside for the Community Integrated Service Systems grants. 15 percent of the balance remaining over $600 million is also for SPRANS. The CISS program is to develop and expand the following: (1) Home visitation; (2) increased participation of obstetricians and pediatricians; (3) integrated service delivery systems; (4) maternal and child health centers for women and infants, under the direction of a not-for-profit hospital; (5) services for rural populations; and (6) integrated state and community service systems for children and youth with special health care needs. First funded in 2004, the Heritable Disorders Program is established to improve the ability of States to provide newborn and child screening for heritable disorders and affect the lives of all of the nation’s infants and children. Newborn and child screening occur at intervals across the life span of every child. Newborn screening universally provides early identification and follow-up for treatment of infants affected by certain genetic, metabolic, hormonal and/or functional conditions. It is expected that newborn and child screening will expand as the capacity to screen for genetic and congenital conditions expands.